To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Kristie L. Kahl
An abnormal protein found in the blood – called monoclonal gammopathy of undetermined significance (MGUS) – may lead to multiple myeloma progression, even after 30 years of disease stability, according to study results published in the New England Journal of Medicine.
Katie Kosko
Tailored survivorship care plans (SCPs) may be beneficial for survivors of head and neck cancer, according to recent research.
Kristie L. Kahl
After a cancer diagnosis and treatment, one may question when they will actually start to feel “normal” again, whatever that may be. The Ovarian Cancer Prognosis and Lifestyle (OPAL) study set out to help women with ovarian cancer to understand just that.
Jason M. Broderick
FDA approves first treatment approved for stage 3 unresectable non-small cell lung cancer to reduce the risk of the cancer progressing, when the cancer has not worsened after chemoradiation.
Katie Kosko
A recent study showed that patients with head and neck cancer who had greater depressive symptoms had shorter survival, higher rates of chemoradiation interruption and poorer treatment response. However, there are ways to manage these symptoms. 
Katie Kosko
Adolescent cancer survivors can improve fitness, cognition and quality of life through increased physical activity, according to study findings presented ahead of the American Society of Clinical Oncology’s (ASCO) Cancer Survivorship Symposium.
Bright Pink
Taking the extra time to have the more difficult conversations with your daughter about her breast health and breast cancer risk has the power to greatly improve and extend her own life.
Silas Inman
Ivosidenib (AG-120) was granted a priority review designation by the Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia (AML), according to a statement from Agios Pharmaceuticals, the company developing the targeted therapy.
Kristie L. Kahl
The availability of sexual aids and resources available to cancer survivors at a wide array of cancer centers appeared disappointingly low, according to survey results to be presented at the 2018 Cancer Survivorship Symposium.
Beth Fand Incollingo
While adolescent and young adult survivors of cancer face an increased risk of long-term complications, many people in this group end up "lost to follow-up," according to recent research.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable